StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following 2Q Beat
August 8, 2016 6:53 AM
Mizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Teva (TEVA): Soft 2Q Underscores Need For Actavis - Piper Jaffray
August 5, 2016 9:03 AM
Teva Pharma (TEVA) Launches Generic Gleevec Tablets in U.S.
August 5, 2016 8:05 AM
Teva Announces Launch of Generic GleevecĀ® Tablets in the United States
August 5, 2016 8:00 AM
Oppenheimer Downgrades Teva Pharma (TEVA) to Perform
August 5, 2016 7:27 AM
Allergan's cash-use plan, pipeline could add to share run
August 4, 2016 1:16 PM
Teva Pharma (TEVA) Tops Q2 EPS by 5c; Guides In-Line
August 4, 2016 7:05 AM
Teva Reports Second Quarter 2016 Results
August 4, 2016 7:00 AM
Biogen not pursuing a sale: source
August 4, 2016 5:52 AM